These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29239578)

  • 21. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
    Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
    Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness.
    Luyten J; Beutels P
    Health Aff (Millwood); 2016 Feb; 35(2):212-8. PubMed ID: 26858372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Financing vaccinations - the South African experience.
    Blecher MS; Meheus F; Kollipara A; Hecht R; Cameron NA; Pillay Y; Hanna L
    Vaccine; 2012 Sep; 30 Suppl 3():C79-86. PubMed ID: 22939027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM
    Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decision support in vaccination policies.
    Piso B; Wild C
    Vaccine; 2009 Oct; 27(43):5923-8. PubMed ID: 19698809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for decision-making on vaccine use: the French experience.
    Loulergue P; Floret D; Launay O
    Expert Rev Vaccines; 2015 Jul; 14(7):917-22. PubMed ID: 25913015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ProVac initiative and evolving decision support.
    Sanderson CF
    Vaccine; 2015 May; 33 Suppl 1():A8-10. PubMed ID: 25919181
    [No Abstract]   [Full Text] [Related]  

  • 28. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
    Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
    Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
    Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Foreword.
    Etienne CF
    Vaccine; 2015 May; 33 Suppl 1():A1. PubMed ID: 25919148
    [No Abstract]   [Full Text] [Related]  

  • 32. [Vaccination programs between individual autonomy and common welfare].
    Marckmann G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Feb; 51(2):175-83. PubMed ID: 18227984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Examining the cost of delivering routine immunization in Honduras.
    Janusz CB; Castañeda-Orjuela C; Molina Aguilera IB; Felix Garcia AG; Mendoza L; Díaz IY; Resch SC
    Vaccine; 2015 May; 33 Suppl 1():A53-9. PubMed ID: 25919175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vaccines: building on scientific excellence and dispelling false myths].
    Signorelli C
    Epidemiol Prev; 2015; 39(3):198-201. PubMed ID: 26522283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of varicella vaccination of healthcare workers.
    Chodick G; Ashkenazi S; Livni G; Lerman Y
    Vaccine; 2005 Oct; 23(43):5064-72. PubMed ID: 16046036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt.
    Ortega O; El-Sayed N; Sanders JW; Abd-Rabou Z; Antil L; Bresee J; Mansour A; Adib I; Nahkla I; Riddle MS
    J Infect Dis; 2009 Nov; 200 Suppl 1():S92-8. PubMed ID: 19817621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs.
    Kimman TG; Boot HJ; Berbers GA; Vermeer-de Bondt PE; Ardine de Wit G; de Melker HE
    Vaccine; 2006 May; 24(22):4769-78. PubMed ID: 16616803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.